pharmaphorum

FEBRUARY 15, 2024

Exercise matched psychotherapy and was more effective than medication as a treatment for #depression in a meta-analysis of randomised clinical trials

119

119

Pharmacy Times

JANUARY 4, 2023

The benefits of physical activity may be greater for children and adolescents with clinical depression or depressive symptoms, who may develop anxiety and other disorders in adulthood.

138

138

The Checkup by Singlecare

FEBRUARY 6, 2024

Comorbidity | Compare symptoms | Depression symptoms | Anxiety symptoms | Overlapping symptoms | When to see a doctor | Treatment | Bottom line 50 million Americans—that’s 1 in 5 people in the country—have a mental health condition like anxiety or depression. What are the symptoms of anxiety and depression?

Vaccines 110

Vaccines 110

STAT

APRIL 9, 2024

Wade in 2022, Texas implemented Senate Bill 8 , which banned abortions for all but the very few who made it to a clinic within about two weeks of missing their period. I was an abortion provider at the time in San Antonio, and the eight months I worked after SB8 took effect were the most depressing of my career.

131

131

Outsourcing Pharma

JULY 24, 2023

Phesi, a global provider of patient-centric data analytics, has released the results of its mid-year global analysis of all clinical trials conducted in 2023 to date.

73

73

Hospital Pharmacy Europe

JUNE 23, 2023

Vortioxetine improves depressive symptoms, cognitive performance, functioning and health-related quality of life in patients with both major depressive disorder and early-stage dementia, according to a recent trial. In a significant proportion of patients, depressive symptoms and dementia are related.

Dosage 94

Dosage Hospitals 94

STAT

NOVEMBER 16, 2023

In 1993, I published “Listening to Prozac,” a book that grew out of my clinical experience prescribing what was then a new class of medications, ones thought to moderate depression through their effect on the way that the brain handles the neurotransmitter serotonin.

138

138

The Checkup by Singlecare

APRIL 15, 2024

People who have depression often have low serotonin levels, but they can correct that imbalance with trazodone , a prescription antidepressant medication that also treats anxiety and sleep disorders. RELATED: Anxiety vs. depression: Compare causes, symptoms, treatments & more How long does it take trazodone to work?

Adverse Reactions 88

Adverse Reactions Dosage Mayo Clinic Labelling 88

The Checkup by Singlecare

FEBRUARY 12, 2024

Depression is not just “feeling down.” When you’re depressed, fatigue affects your ability to function in the daytime and impacts your sleep schedule, diet, and exercise habits. When you’re depressed, fatigue affects your ability to function in the daytime and impacts your sleep schedule, diet, and exercise habits.

Dosage 105

Dosage 105

The Checkup by Singlecare

FEBRUARY 2, 2024

The idea that new parents are supposed to be full of bliss is just one of the reasons that postpartum depression (PPD), also called perinatal depression, often goes undetected. Unfortunately, symptoms of postpartum depression go untreated for the same reasons. What is postpartum depression? One in 8 women in the U.S.

Hospitals 103

Hospitals FDA 103

European Pharmaceutical Review

AUGUST 7, 2023

The US Food and Drug Administration ( FDA ) has approved Zurzuvae ( zuranolone ), the first oral medicine to treat postpartum depression (PPD) in adults. FDA approval of Zurzuvae for postpartum depression was granted to Sage Therapeutics, Inc. Historically, treatment for PPD has been only available as an IV injection.

FDA 80

FDA 80

The Checkup by Singlecare

JANUARY 24, 2024

Whether you need support during a short-term period of grief and loss or you live with long-term depression , your healthcare provider may recommend the use of an antidepressant. 5 most common types of depression medications There are several classes of depression medications to choose from. Jones , Pharm.D.,

Mayo Clinic 103

Mayo Clinic FDA Dosage 103

STAT

APRIL 17, 2024

health regulator last year approved the company’s and partner Biogen’s pill Zurzuvae as a treatment for postpartum depression, but rejected it for clinical depression, which is a much larger market. The failure is the latest hurdle for Sage Therapeutics after the U.S.

Insurance Coverage 96

Insurance Coverage FDA Insurance 96

European Pharmaceutical Review

JULY 19, 2023

Phase II study results for navacaprant (NMRA-140), a novel kappa opioid receptor (KOR) antagonist for major depressive disorder (MDD) demonstrated significant and clinically meaningful improvement in depression for participants. When it first commenced, the clinical trial enrolled only mild-to-moderate MDD US patients.

97

97

European Pharmaceutical Review

SEPTEMBER 29, 2023

The US Food and Drug Administration (FDA) has approved Exxua (gepirone hydrochloride extended-release tablets) for adults with major depressive disorder ( MDD ). “Exxua is the first 5-HT1a agonist with superior efficacy versus placebo as MDD monotherapy, yet did not differ from placebo in rates of sexual dysfunction in clinical trials.

FDA 96

FDA 96

Outsourcing Pharma

NOVEMBER 28, 2023

Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.

76

76

STAT

OCTOBER 13, 2022

Relmada Therapeutics said Thursday that its experimental treatment for depression failed to achieve the primary goals of a large clinical trial, a significant setback for the company’s only medicine in clinical development. Continue to STAT+ to read the full story…

99

99

STAT

AUGUST 4, 2023

The Food and Drug Administration on Friday approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition. But the agency denied the company’s application for an indication for major depression, a much larger potential market.

FDA 98

FDA Labelling 98

Drug Topics

MAY 16, 2023

Panelists address factors driving clinical inertia in treatment-resistant depression.

98

98

European Pharmaceutical Review

JULY 28, 2023

Publication of results of the Phase III SKYLARK study “is a pinnacle moment in treating postpartum depression ( PDD ),” stated Dr Kristina M Deligiannidis, Professor at the Institute of Behavioral Science at the Feinstein Institutes, the trial’s principal investigator, lead author of the paper. At day 45, 61.9

FDA 94

FDA 94

STAT

NOVEMBER 7, 2023

Prescriptions for ketamine have soared in recent years, driven by for-profit clinics and telehealth services offering the medication as a treatment for pain, depression, anxiety and other conditions. WASHINGTON (AP) — As U.S.

114

114

STAT

SEPTEMBER 13, 2023

Over more than a decade working with immigrant farmworkers in the public clinics of the Santa Clara River Valley, Rosemary Hernandez has seen many new moms struggle during the postpartum period. Their isolation and vulnerability compounded the challenges of caring for a newborn, and drove many of these mothers into anxiety and depression.

Compounding 141

Compounding 141

STAT

JULY 31, 2023

Flow Neuroscience, a small Swedish company treating depression with brain-stimulating headsets, released early data on Monday showing that its device relieved depressive symptoms in clinical trials.    The company has not yet formally written up the data for a journal.

FDA 98

FDA 98

STAT

NOVEMBER 7, 2023

WASHINGTON — Current and former government officials proffered a clear-eyed, and often depressing, take Tuesday on the state of clinical trials, the pharmaceutical industry, and biotech investors coming out of the Covid-19 pandemic.

Vaccines 116

Vaccines FDA 116

European Pharmaceutical Review

SEPTEMBER 20, 2022

New data supports the potential use of Biogen’s and Sage Therapeutics’ zuranolone as a potential episodic treatment for people with major depressive disorder (MDD). Zuranolone is an investigational oral 14-day treatment under clinical development for adult patients with MDD and postpartum depression.

Labelling 92

Labelling 92

Pharmacy Times

OCTOBER 13, 2022

Experts discuss the clinical and economic impact of misdiagnosing bipolar I disorder as major depressive disorder.

123

123

STAT

AUGUST 7, 2023

Food and Drug Administration approved a new, rapid-acting medicine made by Sage Therapeutics to treat postpartum depression, the first oral treatment for the condition , STAT writes. But the agency rejected an indication for major depression, a much larger potential market. Analysts noted major depression is a much larger market.

Mayo Clinic 98

Mayo Clinic FDA 98

STAT

MARCH 28, 2023

Intra-Cellular Therapies, maker of an approved treatment for schizophrenia and bipolar depression, announced positive results from a new clinical trial on Tuesday that could potentially expand use of its drug to other types of mood disorders. Sales of the Intra-Cellular drug, called Caplyta, tripled last year to $249 million.

96

96

European Pharmaceutical Review

NOVEMBER 4, 2022

A new report in the New England Journal of Medicine for the largest-ever trial observing the effects of psilocybin in patients with treatment-resistant depression, found participants reported reduced depressive symptoms three weeks after being given 25mg of psilocybin (COMP360) in combination with psychological support.

99

99

Pharmaceutical Technology

JANUARY 4, 2024

SP-624 is under clinical development by Sirtsei Pharmaceuticals and currently in Phase II for Major Depressive Disorder.

75

75

STAT

NOVEMBER 3, 2022

Since the late ’90s, Kathy Wallace has been battling major depression with a series of drugs — first Prozac, then three others, and back again to Prozac. When the 53-year-old researched nearby clinics, though, she found them out of reach. But in the last six months, nothing seemed to be helping.

Labelling 118

Labelling 118

STAT

JULY 6, 2023

Traumatic brain injury multiplies the risk of major depression eightfold. While the emotional trauma of whatever caused such deep damage may be understandable, from a blast in a war zone to a blow on the playing field, there’s a physiological component, too, that neuroscientists have long suspected but have been unable to identify.

Medical Schools 101

Medical Schools Hospitals 101

Hospital Pharmacy Europe

MARCH 30, 2023

In the World Health Organisation European Region, depression is estimated to affect roughly 4.3% (or 40 million people) of the population. In addition, a US study of 36,309 adults reported that the 12-month and lifetime prevalence’s of major depressive disorder were 10.4% Treatment-resistant depression (i.e.,

Communication 98

Communication Hospitals 98

European Pharmaceutical Review

JUNE 28, 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a first-of-its-kind trial to run this year to test psychedelic drugs as a treatment for major depressive disorder (MDD). The clinical trial will combine dosages of a new psilocin-based drug with specialist therapy.

Dosage 82

Dosage FDA 82

The Checkup by Singlecare

APRIL 17, 2024

Continue reading to learn more about Latuda for bipolar depression. A clinical trial published in 2014 found that after six weeks, adult patients who took Latuda had a significant improvement in symptoms of bipolar depression. When starting this medication, you may want to know how long Latuda will take to work.

Dosage 52

Dosage FDA 52

Fierce Healthcare

JUNE 28, 2023

Calm Health, the mental health offering of meditation app Calm, is tapping the Mayo Clinic to help design digital mental health programs to help cancer patients manage anxiety, depression and menta | The upcoming digital mental health program will be available to Calm Health customers and “will be designed for all adults with cancer,” according to (..)

Mayo Clinic 110

Mayo Clinic 110

STAT

JULY 31, 2023

Cheryl Meier had watched clinical trial enrollment announcements for years — but always for her sons’ type 1 diabetes, never for herself. But it never worked for her dark thoughts.

FDA 93

FDA 93